Q3 Earnings Forecast for ESPR Issued By HC Wainwright

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Investment analysts at HC Wainwright issued their Q3 2025 EPS estimates for Esperion Therapeutics in a report issued on Tuesday, March 4th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($0.15) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at $0.06 EPS and FY2028 earnings at $0.20 EPS.

Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald started coverage on Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target on the stock. JMP Securities restated a “market outperform” rating and set a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. The Goldman Sachs Group started coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, StockNews.com downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $6.75.

Esperion Therapeutics Stock Performance

Esperion Therapeutics stock opened at $1.59 on Friday. The stock has a market cap of $313.29 million, a P/E ratio of -2.48 and a beta of 1.01. Esperion Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $3.94. The firm’s fifty day moving average price is $1.97 and its 200-day moving average price is $2.08.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ESPR. Cibc World Markets Corp bought a new stake in shares of Esperion Therapeutics in the fourth quarter worth about $39,000. SJS Investment Consulting Inc. bought a new stake in shares of Esperion Therapeutics in the fourth quarter worth about $55,000. Versor Investments LP bought a new stake in shares of Esperion Therapeutics in the third quarter worth about $44,000. Crestline Management LP bought a new stake in shares of Esperion Therapeutics in the fourth quarter worth about $63,000. Finally, SLT Holdings LLC bought a new stake in shares of Esperion Therapeutics in the fourth quarter worth about $66,000. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.